Olema Net Tangible Assets from 2010 to 2026
| OLMA Stock | USD 23.75 0.10 0.42% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 227.2 M | Current Value 176.7 M | Quarterly Volatility 126 M |
Check Olema Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Olema Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Interest Income of 15.3 M or Depreciation And Amortization of 474.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.79. Olema financial statements analysis is a perfect complement when working with Olema Pharmaceuticals Valuation or Volatility modules.
Olema | Net Tangible Assets | Build AI portfolio with Olema Stock |
Analyzing Olema Pharmaceuticals's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Olema Pharmaceuticals's current valuation and future prospects.
Latest Olema Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Olema Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Olema Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Olema Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Olema Net Tangible Assets Regression Statistics
| Arithmetic Mean | 91,304,016 | |
| Geometric Mean | 28,296,455 | |
| Coefficient Of Variation | 137.99 | |
| Mean Deviation | 115,310,137 | |
| Median | (6,278,000) | |
| Standard Deviation | 125,992,217 | |
| Sample Variance | 15874T | |
| Range | 348.7M | |
| R-Value | 0.76 | |
| Mean Square Error | 7212.2T | |
| R-Squared | 0.57 | |
| Significance | 0.0004 | |
| Slope | 18,903,859 | |
| Total Sum of Squares | 253984.6T |
Olema Net Tangible Assets History
About Olema Pharmaceuticals Financial Statements
Olema Pharmaceuticals stakeholders use historical fundamental indicators, such as Olema Pharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Olema Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Olema Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Olema Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Olema Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 227.2 M | 176.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:Check out the analysis of Olema Pharmaceuticals Correlation against competitors. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. Anticipated expansion of Olema directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Olema Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Olema Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Olema's balance sheet. Smart investors calculate Olema Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Olema Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Olema Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Olema Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.